Three Sinus Surgeries In: Desensitizing to Aspirin or Adding a Biologic
A patient whose asthma and nasal polyps are both driven by the same disease, choosing between a therapy that has repeatedly failed to hold and two newer options with no trial ever comparing them directly.
Simone R. teaches high school chemistry and has, by her own count, lost her sense of smell and gotten it back four separate times — once for each sinus surgery, briefly, before the polyps grew back and took it again. Her asthma and her sinus disease have never really behaved like two separate problems; they flare together, and the one time in her twenties she took ibuprofen for a headache without thinking about it, both flared hard enough to send her to an emergency department. She is three functional endoscopic sinus surgeries into a disease that keeps returning to the same place, still symptomatic on high-dose inhaled corticosteroid-LABA and montelukast, and the conversation today is about what actually changes the underlying disease rather than the fourth surgery treating its latest regrowth.
Two real options sit in front of her, and the literature is honest that nobody has ever compared them head-to-head. Aspirin therapy after desensitization — building tolerance through escalating doses, then staying on daily aspirin indefinitely — is the older, better-studied approach specifically for reducing polyp regrowth and repeat surgery, the exact failure pattern Simone has lived three times over. Dupilumab, approved for both severe asthma and CRSwNP, treats the same IL-4/13-driven inflammation from a different angle and carries none of aspirin therapy’s real gastrointestinal burden. That burden is worth stating at its measured size rather than its reputation: the AAAAI work group report on aspirin desensitization names gastrointestinal toxicity as the leading reason patients stop, and the published series put discontinuation at roughly fourteen to sixteen percent — a real minority, and the single likeliest way this therapy fails her, but not the coin-flip it is sometimes described as. Simone belongs to the group those rates were measured in, and she has never tried it. What the evidence does not offer is a trial telling her, or her team, which one actually works better for a person in exactly her situation.
After a third sinus surgery, choosing what actually changes the disease
She has had three surgeries and three regrowths, and aspirin therapy after desensitization is specifically the better-studied option for exactly that outcome — the AAAAI work group report on aspirin desensitization and the placebo-controlled trials behind it put reduced polyp regrowth and fewer repeat procedures at the center of what this therapy is for. She has never actually attempted it. Before we reach for a biologic, I would want the therapy with the strongest evidence for the specific failure pattern she keeps living through to actually be tried.
I understand the case for treating the surgical-recurrence pattern directly. What I would weigh against it is that dupilumab carries a dual indication covering both her asthma and her CRSwNP in one agent, and it does not carry aspirin therapy’s gastrointestinal burden — which the published series put at roughly fourteen to sixteen percent stopping, most often for exactly that reason. I want to be careful not to inflate that: it is a minority, not a majority. But she has been through three surgeries and years of incomplete control already, and something close to a one-in-six chance that the therapy we ask her to commit to indefinitely ends in her stopping it is worth weighing against an alternative that carries no such rate at all.
I am not disputing the desensitization evidence for surgical recurrence specifically — I am asking whether the better-studied option is automatically the better first option for someone this fatigued by treatment, when its likeliest failure mode is not that it does not work but that she stops taking it.
I want to name something plainly rather than let it sit underneath this disagreement: no trial has ever compared these two approaches head-to-head. Neither of you is arguing from evidence that ranks one above the other — you are each arguing from real evidence about a different piece of her disease. I think the honest way to decide is to ask Simone directly which burden weighs on her more right now, the surgical recurrence or the years of incomplete asthma and sinus control, and let that answer, not a specialist default, choose the starting point — with the option genuinely open to add the other later rather than treating this as a single, permanent choice.
Agreed: start dupilumab, chosen after Simone identified her incomplete day-to-day asthma and sinus control as the burden weighing on her more heavily right now, ahead of the surgical-recurrence question specifically.
Explicitly not agreed to be closed: aspirin desensitization remains on the table as a later addition if polyp regrowth continues despite dupilumab — framed to Simone as a sequencing decision, not a one-time fork where the other path disappears.